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SIONS: Our model provides evidence than an effective
AIDS intervention in a high-risk population of out-of-
treatment substance abusers can avert significant num-
bers of new HIV infections, which may offset initial
costs.
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ECONOMIC EVALUATION OF ROTAVIRUS 
VACCINATION FOR THE NETHERLANDS
Welte R, Jager J, van Duynhoven Y, de Wit M
National Institute of Public Health and the Environment, 
Bilthoven, Netherlands
OBJECTIVES: To estimate the cost-effectiveness of a na-
tional rotavirus (RV) vaccination program for the Neth-
erlands, from a societal perspective. METHODS: Three
RV-vaccine doses are administered to infants as part of
the routine schedule of childhood immunizations. Based
on clinical trials we assume a vaccine protection duration
of 4 years and a vaccine effectiveness of 55% against
mild RV-diarrhea, 65% against moderate RV-diarrhea
(outpatient treatment), and 80% against severe RV-diar-
rhea (inpatient treatment). Resource consumption caused
by RV-diarrhea is derived from recent national studies
and the findings of expert panels and valued according to
the Dutch costing guidelines. Direct medical (e.g., for
vaccine administration or RV-tests) and non-medical
costs (e.g., for transportation or extra diapers) are con-
sidered. Indirect costs include the productivity loss of
paid (friction cost method) and unpaid work (substitu-
tion approach) caused by parents caring for their sick
child. Costs are presented in 1998 EUR and both future
costs and effects are discounted at 4%. A decision analy-
sis model is employed to calculate the health outcomes
and costs of the vaccination program. RESULTS: RV-
vaccination would avoid 34,300 cases of gastroenteritis
and 2,300 hospitalizations per year. The break-even dose
price of the vaccine is EUR 4 or EUR 9, depending on the
exclusion or inclusion of the productivity loss of unpaid
work. However, at a dose price of the 1999 withdrawn
RV-vaccine (EUR 30) the program would yield costs of
EUR 15,000 (paid work only) or EUR 12,100 (paid and
unpaid work) per avoided hospitalization. These results
are sensitive to the incidence of RV-gastroenteritis, the
vaccine effectiveness, the length of hospitalization, and
the productivity loss caused by RV-gastroenteritis while
variations in outpatient care and direct non-medical costs
have limited influence. CONCLUSIONS: Depending on
its price the RV-vaccine might be a promising candidate
for the Dutch national immunization program.
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OBJECTIVE: Studies evaluating predictors of heath-
related quality-of-life (HRQOL) in patients infected with
HIV have primarily been limited to clinical, sociodemo-
graphic, and psychological factors. Little is known about
the relationship between HRQOL and behaviors such as
medication adherence or complementary and alternative
medicine (CAM) use. The purpose of this study was to
determine the clinical, sociodemographic, and behavioral
predictors of HRQOL. METHODS: A sample of 242
HIV-infected patients was recruited. Data were collected
using a self-administered instrument containing the Med-
ical Outcomes Study (MOS)-HIV Health Survey and
items relating to CAM use, medication adherence, and
sociodemographic characteristics. Clinical information
was abstracted from medical records. Independent asso-
ciations of the Mental (MHS) and Physical Health Sum-
mary (PHS) scores with CD4 cell counts, HIV-1 viral
loads, CAM use, self-reported medication adherence, an-
tiretroviral use, and sociodemographic characteristics
were assessed. Linear regression models were created for
each score. Variables independently associated (p  0.05)
with a score were entered into that model. RESULTS: The
mean MHS and PHS scores were 46.6 and 42.8, respectively.
Education, income, CAM use, and self-reported adher-
ence to HIV medication regimens were independently as-
sociated (p  0.03) with MHS scores. PHS scores were
independently associated (p  0.003) with age, income,
HIV-1 viral load, CD4 count, and CAM use. In the mul-
tivariate analyses, income and self-reported adherence
were found to be significant (p  0.005) predictors of the
MHS scores (Adj. R2  0.197); age, income, CD4
counts, and CAM use were found to be significant (p 
0.03) predictors of PHS scores (Adj. R2  0.182). CON-
CLUSIONS: Our research suggests that, along with clini-
cal and sociodemographic characteristics, self-reported
behaviors are important predictors of HRQOL among
HIV-infected patients.
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BACKGROUND: Clinical trials have shown that highly
active antiretroviral therapy (HAART) alters the natural
progression of HIV. This study was undertaken to deter-
mine if, apart from the beneficial clinical impact, there
has been a change in the cost of AIDS-related care.
METHODS: Data from the Massachusetts (MA) Depart-
ment of Public Health and hospital discharge databases
for 1995–1998 were used to examine changes in hospital
admission and discharge patterns, and hospital costs for
adults with AIDS across the four years. Analyses involved
log transformation to address highly skewed distribu-
tions, ANOVA to compare continuous variables and Chi-
Square to compare the proportions. Hospital costs in-
